Home » Topics » U.S., BioWorld Asia

U.S., BioWorld Asia
RSS

Hifibio advancing toward IND filings with $67M series C

Sep. 4, 2019

BEIJING – Multinational antibody specialist Hifibio Therapeutics Inc. said it closed a $67 million series C financing round to advance its drug candidates for cancer and autoimmune disorders.

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

U.S., BioWorld Asia RSS

U.S., BioWorld Asia
RSS